Compare Gilead Sciences, Inc. (GILD) vs Simon Property Group Inc (SPG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Simon Property Group Inc — how do they compare? Gilead Sciences, Inc. trades at $133.73 (market cap $163.51B), while Simon Property Group Inc trades at $227.16 (market cap $72.00B). The key difference: Gilead Sciences, Inc. is far larger — about 2.3× Simon Property Group Inc's market cap, and Simon Property Group Inc pays the higher dividend (3.96%). Which is the better fit depends on your goals.
| GILD | SPG | |
|---|---|---|
Market Cap | $163.51B | $72.00B |
Sector | Health | Real Estate |
52-Week High | $155.80 | $227.56 |
52-Week Low | $108.22 | $160.68 |
Enterprise Value | $178.05B | $100.48B |
Dividend Yield | 2.49% | 3.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
SPG trades at $227.16, up 2.66% today, with a bullish technical signal supported by moving averages. The company reported strong earnings beats in recent quarters, including Q1 2026 EPS of $1.48 versus $1.46 expected. Revenue grew to $6.36B in 2025 with a net income margin of 70.59%, though cash flow trends show a net outflow of -$577M. Analyst consensus is mixed with 40.54% buy ratings but a price target of $214.40 below the current price.
Outlook remains positive due to robust leasing activity and raised guidance, but risks include high leverage with $24.21B long-term debt and sensitivity to interest rates. The stock's valuation metrics like P/E of 15.44 appear reasonable, yet investor caution is warranted given the negative net cash flow and competitive pressures from e-commerce.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Simon Property Group Inc
Simon Property Group is the second- largest real estate investment trust in the United States. Its portfolio includes an interest in 207 properties: 119 traditional malls, 69 premium outlets, 14 Mills centers (a combination of a traditional mall, outlet center, and big-box retailers), six lifestyle centers, and five other retail properties. Simon's portfolio averaged $693 in sales per square foot over the 12 months prior to the pandemic. The company also owns a 21% interest in Klepierre, a European retail company with investments in shopping centers in 16 countries, and joint venture interests in 33 premium outlets across 11 countries.
Read more on SPG →
